Article
Biochemistry & Molecular Biology
Takashi Matsuhira, Osamu Nishiyama, Yuji Tabata, Shinji Kurashimo, Hiroyuki Sano, Takashi Iwanaga, Yuji Tohda
Summary: The study showed that AA6216 could significantly suppress the accumulation of SatMs in the lungs of mice and also dose-dependently inhibit the production of TNF-α by SatMs.
BIOCHEMISTRY AND BIOPHYSICS REPORTS
(2021)
Article
Immunology
Xiaoyu Wan, Yongtao Xiao, Xinbei Tian, Ying Lu, Haiqing Chu
Summary: The aim of this study is to investigate the roles of CD11b+ monocytes/macrophages in the progression of pulmonary fibrosis. The expression levels of CD11B gene and inflammatory genes in IPF patients are evaluated. CD11b cells are conditionally depleted in CD11b-DTR mice and pulmonary fibrosis is induced using bleomycin. The results show that CD11b+ monocytes/macrophages contribute to pulmonary fibrosis and represent a potential therapeutic target for IPF.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Yasuyoshi Miyata, Tomohiro Matsuo, Yuichiro Nakamura, Kensuke Mitsunari, Kojiro Ohba, Hideki Sakai
Summary: Erectile dysfunction (ED) causes mental distress and decreases the quality of life for patients and their partners. Phosphodiesterase type 5 (PDE5) inhibitors are the standard treatment for ED, but effective in only a subgroup of patients. Macrophages play important roles in ED and Peyronie's disease (PD), but more research is needed to fully understand the pathological mechanisms involved.
Article
Immunology
Qiujie Luo, Dawei Deng, Yang Li, Hongjie Shi, Jinping Zhao, Qiaofeng Qian, Wei Wang, Jie Cai, Wenjun Yu, Jinping Liu
Summary: This study investigated the role of TREM2 in macrophage regulation and its potential therapeutic implications for pulmonary fibrosis. The results showed that TREM2 insufficiency could inhibit pulmonary fibrosis and M2 macrophage polarization through the activation of the STAT6 pathway and regulation of fibrotic factors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Afsal Kolloli, Santhamani Ramasamy, Ranjeet Kumar, Annuurun Nisa, Gilla Kaplan, Selvakumar Subbian
Summary: This study suggests that CC-11050 may be a potential therapy to alleviate inflammation and fibrosis in COVID-19 cases.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Franziska Elena Herrmann, Christian Hesslinger, Lutz Wollin, Peter Nickolaus
Summary: BI 1015550, a novel PDE4 inhibitor, shows promising anti-inflammatory and antifibrotic potential in vitro and in vivo, suggesting it as a potential candidate for the treatment of idiopathic pulmonary fibrosis and other fibro-proliferative diseases.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Qingfang Li, Yuan Cheng, Zhe Zhang, Zhenfei Bi, Xuelei Ma, Yuquan Wei, Xiawei Wei
Summary: This study found that inhibiting ROCK can treat pulmonary fibrosis by regulating macrophage polarization. The newly designed unselective ROCK inhibitor WXWH0265 has a good protective effect in improving pulmonary fibrosis. These results provide empirical evidence for using WXWH0265 as a potential drug for preventing pulmonary fibrosis.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Shengnan Qiu, Xianglei Fu, Yanbin Shi, Hengchang Zang, Yunpeng Zhao, Zhilong Qin, Guimei Lin, Xiaogang Zhao
Summary: In this study, porous microspheres loading RLX (RLX@PMs) were developed and evaluated for their therapeutic potential on IPF through aerosol inhalation. The results showed that RLX@PMs can release the drug for a prolonged period of time, maintaining its peptide structure and activity. RLX@PMs protected mice from excessive collagen deposition and architectural distortion, and improved compliance after inhalation administration. They also showed better safety compared to pirfenidone. Moreover, RLX@PMs ameliorated collagen gel contraction and suppressed macrophage polarization, which may explain their ability to reverse fibrosis. Therefore, RLX@PMs represent a promising strategy for IPF treatment.
MOLECULAR PHARMACEUTICS
(2023)
Article
Environmental Sciences
Fuyang Jiang, Qiyue Jiang, Jing Zhao, Zhonghui Zhu, Qiyue Jia, Wenming Xue, Hongwei Wang, Yan Wang, Lin Tian
Summary: Silica can induce macrophage pyroptosis, which plays an important role in activating myofibroblasts during the progression of silicosis. Inhibiting macrophage pyroptosis could be a feasible clinical strategy to alleviate silicosis.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
(2023)
Article
Biochemistry & Molecular Biology
Yuanhua Lu, Jianan Zhao, Yafei Tian, Dan Shao, Zhiqi Zhang, Siqi Li, Jialin Li, Hugang Zhang, Wei Wang, Ping Jiao, Jie Ma
Summary: The study demonstrates that Men1 has conflicting roles in pulmonary fibrosis, as it attenuates fibrosis by inhibiting fibroblast activation and promoting macrophage fibrotic phenotype and migration. The profibrotic role of Men1 in macrophages may be mediated by regulating macrophage pyroptosis and OPN expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Natsuki Kubota-Ishida, Takashi Matsuhira, Chizuko Kaji, Chika Kikuchi, Yuji Tabata
Summary: The study compared the effects of a novel PDE4 inhibitor, AA6216, with crisaborole on skin inflammation, showing that AA6216 is a more potent inhibitor of PDE4 and of cytokine production. In mouse models of dermatitis, AA6216 significantly suppressed skin inflammation, suggesting its potential as a novel and effective topical therapeutic agent for the treatment of dermatitis including AD.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Plant Sciences
Mengyao Xie, Lehe Yang, Jiayun Cheng, Hongyan Qu, Yanting Gu, Cheng Ding, Xiaomei Xu, Chengguang Zhao, Xiaoying Huang, Liangxing Wang
Summary: This study demonstrates that gracillin improves lung function, reduces lung inflammation and mitigates collagen deposition to ameliorate BLM-induced PF in mice. Gracillin also suppresses TGF-β1-induced increases in ECM deposition and migration, and inhibits the phosphorylation and nuclear translocation of STAT3. The decreased ECM deposition and migration upon gracillin treatment are abrogated upon overexpression of STAT3 in NIH-3T3 cells.
JOURNAL OF ETHNOPHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Ting Pan, Qing Zhou, Kang Miao, Lei Zhang, Guorao Wu, Jun Yu, Yongjian Xu, Weining Xiong, Yong Li, Yi Wang
Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic and diffuse lung disease of unknown etiology with a fatal outcome. Current treatment strategies have not shown significant positive impact on prognosis. Nanomedicine-based gene therapy targeting macrophage polarization may offer a promising strategy for the treatment of pulmonary fibrosis.
Review
Pharmacology & Pharmacy
Xudan Yang, Zhihao Xu, Songhua Hu, Juan Shen
Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease without a known cause. Current approved drugs for IPF, such as Pirfenidone and Nintedanib, can slow down the decline in lung function and reduce the risk of acute worsening. However, they cannot alleviate symptoms or improve overall survival. The development of new, safe, and effective drugs is necessary. Previous studies have shown that cyclic nucleotides and phosphodiesterase inhibitors may be potential targets for treating pulmonary fibrosis. This paper reviews the progress in research on PDE inhibitors and provides insights for the development of anti-pulmonary fibrosis drugs.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Immunology
Bowen Liu, Qiuyan Jiang, Ruxuan Chen, Shaoyan Gao, Qin Xia, Jingyan Zhu, Fangxia Zhang, Chi Shao, Xiangning Liu, Xiaohe Li, Honggang Zhou, Cheng Yang, Hui Huang
Summary: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by excessive proliferation of fibroblasts and the distortion of alveolar architecture. In this study, tacrolimus was found to suppress the polarization of M2 macrophages and alleviate fibrosis progression by inhibiting pro-fibrotic factors and targeting the JAK2/STAT3 signaling pathway.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)